Saby George

1998–2025 年に発表

76: 論文数
20,814: 被引用数
43: h 指数
73: i10 指数

被引用数

引用元

国・地域

0%24.4%その他 23.3%

機関

分野

トピック

全論文

並び替え

検索で開く

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 被引用: 4,643
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
著者: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 被引用: 5,890
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
著者: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Payal Kapur, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Mary A. Dwyer, Lisa A. Gurski, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2022 被引用: 655
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
著者: Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Terence W. Friedlander, Rana R. McKay, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, J.P. Maroto Rey, Christiano Ferrario, Anne‐Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg - Journal of Clinical Oncology 2023 被引用: 175
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
著者: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 被引用: 263
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
著者: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, Shruti Shally Saggi, M. Brent McHenry, Robert J. Motzer - ESMO Open 2020 被引用: 522
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
著者: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 被引用: 780
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
著者: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 被引用: 337
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
著者: Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood, Sebastiano Battaglia, Saby George, Gurkamal Chatta, Igor Puzanov, Carl Morrison, Kunle Odunsi, Brahm H. Segal, Grace K. Dy, Marc S. Ernstoff, Fumito Ito - Nature Communications 2021 被引用: 187
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
著者: Robert J. Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Żurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C. Goh, Dingwei Ye, Alejo Lingua, Jean‐Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey A. Sosman, Michael Staehler, Sergio Vázquez Estévez, Burçin Şimşek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex - The Lancet 2023 被引用: 172
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
著者: Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist, Toni K. Choueiri, Saby George, Brett Hughes, Matthew D. Hellmann, Dale R. Shepard, Brian I. Rini, Shivaani Kummar, Amy Weise, Matthew J. Riese, Ben Markman, Leisha A. Emens, Daruka Mahadevan, Jason J. Luke, Ginna G. Laport, Joshua Brody, Leonel F. Hernandez‐Aya, Philip Bonomi, Jonathan W. Goldman, Lyudmyla Berim, Daniel J. Renouf, Rachel Goodwin, Brian Munneke, Po Y. Ho, Jessica Hsieh, Ian McCaffery, Long Kwei, Stephen B. Willingham, Richard A. Miller - Cancer Discovery 2019 被引用: 339
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
著者: Robert J. Motzer, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, B. Yа. Alekseev, Sun Young Rha, Jaime R. Merchan, Jeffrey C. Goh, Aly‐Khan A. Lalani, Ugo De Giorgi, Bohuslav Melichar, Sung‐Hoo Hong, Howard Gurney, María José Méndez, Evgeny Kopyltsov, Sergei Tjulandin, Teresa Alonso‐Gordoa, Vadim Kozlov, Anna Alyasova, Eric Winquist, Pablo Maroto, Miso Kim, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Karla Rodriguez-Lopez, Joseph E. Burgents, Cixin He, Chinyere E. Okpara, Jodi A. McKenzie, Toni K. Choueiri, for the CLEAR Trial Investigators, Robert J. Motzer, Toni K. Choueiri, Thomas E. Hutson, Luke T. Nordquist, David R. Spigel, Jaime R. Merchan, Saby George, Sandhya Srinivas, Brendan D. Curti, Andrew Pippas, Elisabeth I. Heath, Subramanya Rao, Theodore Stewart Gourdin, Mehmood Hashmi, Nafisa Burhani, Ana M. Molina, Alan J. Koletsky, Robert Alter, C. Alemany, Benjamin A. Gartrell, Mike Cusnir, Harsha Vyas, Stephanie L. Graff, Christian Squillante, Mark Knapp, Ivor Percent, Vijay Patel, Daniel L. Spitz, C. Harkness, Marc Matrana, Lindsay Overton, Stephen Richey, Donald Richards, Habib M. Ghaddar, Robert Galamaga, Ralph J. Hauke, Joseph Haggerty, Ronald Harris, Mark Johns, Samith T. Kochuparambil, Christian Kollmannsberger, Bobby Shayegan, Christina Canil, Eric Winquist, Catherine Sperlich, Georg A. Bjarnason, Naveen S. Basappa, Wolfgang Loidl, Wolfgang Horninger, Manuela Schmidinger, Lionel D’Hondt, Dirk Schrijvers, Annemie Rutten, Peter Schatteman, Wim Wynendaele, Daisy Luyten, Spyridon Sideris, Christine Gennigens, Bohuslav Melichar, Jana Katolická, Jiří Tomášek, Jana Prausová, Tomáš Büchler ほか 141 名 - Journal of Clinical Oncology 2024 被引用: 158
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
著者: Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Margolin, Elizabeth R. Plimack, Alexandre Lambert, Ian M. Waxman, Hans J. Hammers - Journal of Clinical Oncology 2014 被引用: 1,078
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
著者: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean‐Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jerónimo Rafael Rodríguez‐Cid, Sumanta K. Pal, André M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini - Clinical Cancer Research 2020 被引用: 242
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
著者: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Thomas Olencki, Jamal Tarazi, Brad Rosbrook, Kathrine C. Fernandez, Mariajosé Lechuga, Toni K. Choueiri - The Lancet Oncology 2018 被引用: 368
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
著者: Brian I. Rini, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George, Thomas Powles, Frede Donskov, Scott S. Tykodi, Sumanta K. Pal, Saurabh Gupta, Chung‐Wei Lee, Ruiyun Jiang, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2022 被引用: 69
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
著者: Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, H.P. Bagshaw, Michael J. Baine, Kathryn E. Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Andrew J. Gunn, Naomi B. Haas, Michael P. Johnson, Payal Kapur, Jennifer King, Christos E. Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon J. Manley, M. Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey A. Sosman, Randy F. Sweis, Matthew R. Zibelman, Ryan Schonfeld, MaryElizabeth Stein, Lisa A. Gurski - Journal of the National Comprehensive Cancer Network 2024 被引用: 166
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
著者: Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon J. Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi B. Haas, Steven Hancock, Christos E. Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley G. Somer, Jeffrey A. Sosman, Mary A. Dwyer, Angela D. Motter - Journal of the National Comprehensive Cancer Network 2020 被引用: 259
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
著者: Robert J. Motzer, Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles, Frede Donskov, Elizabeth R. Plimack, Philippe Barthélémy, Hans J. Hammers, Saby George, Viktor Grünwald, Camillo Porta, Victoria Neiman, Alain Ravaud, Toni K. Choueiri, Brian I. Rini, Pamela Salman, Christian Kollmannsberger, Scott S. Tykodi, Marc‐Oliver Grimm, Howard Gurney, Raya Leibowitz‐Amit, Poul Geertsen, Asim Amin, Yoshihiko Tomita, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Journal for ImmunoTherapy of Cancer 2020 被引用: 225
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
著者: David Cella, Viktor Grünwald, Bernard Escudier, Hans J. Hammers, Saby George, Paul Nathan, Marc‐Oliver Grimm, Brian I. Rini, Justin Doan, Cristina Ivanescu, Jean Paty, Sabeen Mekan, Robert J. Motzer - The Lancet Oncology 2019 被引用: 254
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
著者: Thomas Powles, Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Camillo Porta, Carlos H. Barrios, Martin Eduardo Richardet, Howard Gurney, Elizabeth R. Kessler, Yoshihiko Tomita, Jens Bedke, Saby George, Christian Scheffold, P. Wang, В. Э. Федоров, Robert J. Motzer, Toni K. Choueiri - ESMO Open 2024 被引用: 91
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
著者: Nizar M. Tannir, Bernard Escudier, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Michael B. Atkins, Christian Kollmannsberger, Marc‐Oliver Grimm, Yoshihiko Tomita, Brian I. Rini, Ruiyun Jiang, Heshani Desilva, Chung‐Wei Lee, Robert J. Motzer - Journal of Clinical Oncology 2024 被引用: 46
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
著者: Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian Kollmannsberger, Howard Gurney, Marc‐Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Toni K. Choueiri, David Leung, Shruti Shally Saggi, Chung‐Wei Lee, M. Brent McHenry, Robert J. Motzer - European Urology 2021 被引用: 80
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
著者: Alice Boilève, Maria I. Carlo, Philippe Barthélémy, Stéphane Oudard, Delphine Borchiellini, Martin H. Voss, Saby George, Christine Chevreau, Judith Landman‐Parker, M-D Tabone, D. D. Chism, A. Amin, Mehmet Asım Bilen, Dominick Bossé, Aurore Coulomb L’Herminé, Xiaoping Su, Toni K. Choueiri, Nizar M. Tannir, Gabriel G. Malouf - Journal for ImmunoTherapy of Cancer 2018 被引用: 98